Credit Suisse Group reaffirmed their outperform rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report released on Thursday, January 18th, Marketbeat Ratings reports. The firm currently has a $147.00 price target on the biopharmaceutical company’s stock.
ALXN has been the subject of a number of other research reports. Leerink Swann reaffirmed a buy rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Monday, October 2nd. Raymond James Financial reiterated an outperform rating and issued a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada increased their price objective on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet downgraded Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have given a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of Buy and an average price target of $152.77.
Alexion Pharmaceuticals (NASDAQ ALXN) opened at $115.43 on Thursday. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. The company has a market cap of $25,790.00, a P/E ratio of 58.59, a price-to-earnings-growth ratio of 0.95 and a beta of 1.16.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same quarter in the prior year, the firm posted $1.26 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. equities research analysts predict that Alexion Pharmaceuticals will post 6.25 EPS for the current fiscal year.
In other news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John B. Moriarty sold 3,363 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $115.70, for a total value of $389,099.10. Following the completion of the transaction, the executive vice president now directly owns 71,400 shares in the company, valued at $8,260,980. The disclosure for this sale can be found here. Insiders sold 28,930 shares of company stock worth $3,378,199 over the last three months. Insiders own 4.35% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALXN. Valeo Financial Advisors LLC purchased a new position in Alexion Pharmaceuticals in the 3rd quarter worth approximately $147,000. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals in the 3rd quarter worth approximately $156,000. BT Investment Management Ltd bought a new stake in Alexion Pharmaceuticals in the 3rd quarter worth approximately $165,000. YorkBridge Wealth Partners LLC increased its stake in Alexion Pharmaceuticals by 221.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 982 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. bought a new stake in Alexion Pharmaceuticals in the 3rd quarter worth approximately $201,000. 94.01% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/13/credit-suisse-group-reaffirms-outperform-rating-for-alexion-pharmaceuticals-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.